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Background: Clostridioides difficile is the most common cause of antimicrobial-associated diarrhoea in
high-income countries. Fluoroquinolone resistance enabled the emergence and intercontinental spread of the
epidemic ribotype (RT) 027 strain of C. difficile in the early 2000s. Despite frequent inappropriate antimicrobial
use in Asia, RT 027 is rarely isolated in the region, but the often fluoroquinolone- and clindamycin-resistant RT
017 strain predominates.
Objectives: This study evaluated the antimicrobial activity of ridinilazole, a novel antimicrobial agent with highly
specific activity for C. difficile, against clinical strains of C. difficile from Asia.
Methods: C. difficile strains from Japan (n = 64), South Korea (n = 32) and China (n = 44) were tested by the
agar dilution method for susceptibility to ridinilazole, metronidazole, vancomycin, clindamycin, moxifloxacin,
rifaximin and fidaxomicin.
Results: All strains were susceptible to ridinilazole, with low MICs (0.03–0.25 mg/L). Several strains showed mul-
tiresistance profiles, particularly RT 017 (100% clindamycin resistant, 91.3% moxifloxacin resistant, 82.6% rifaxi-
min resistant) and RT 369 (94.4% clindamycin resistant, 100% moxifloxacin resistant). Rifaximin resistance was
absent in all strains from Japan. Multiresistance to clindamycin, moxifloxacin and rifaximin was found in 19 RT
017 strains (from China and South Korea), 2 RT 001 strains (South Korea) and 1 RT 046 strain (South Korea).
Conclusions: Ridinilazole showed potent activity against a range of Asian C. difficile strains, which otherwise fre-
quently displayed resistance to several comparator antimicrobial agents. Ongoing surveillance of antimicrobial
resistance profiles is required to monitor and control the spread of resistant strains.
Introduction
Clostridioides difficile has emerged in the 21st century as the most
common cause of healthcare-associated diarrhoea in high-
income countries.1 Outbreaks of C. difficile infection (CDI) in the
early 2000s brought increased mortality across North America and
Europe, driving researchers to investigate CDI epidemiology and
C. difficile virulence further to determine how best to control its
spread. In the ensuing years, infection prevention and control
measures, including enhanced disinfection and antimicrobial
stewardship, have had mixed results in curbing the transmission of
C. difficile within hospitals, while a growing body of evidence is
showing community-based transmission is increasing.2
C. difficile causes diarrhoea via production of three different tox-
ins, toxin A, toxin B and binary toxin (CDT), in several combinations,
the most common being A!B!CDT#, followed by A#B!CDT#
and A!B!CDT!, while A#B#CDT# strains are incapable of
causing disease but can colonize the gut. Other combinations of
toxin profiles are rare.
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Another key virulence factor of C. difficile is intrinsic and
acquired resistance to an array of antimicrobial agents, which has
helped drive expansion of C. difficile around the globe in recent
decades, influenced by overuse of antimicrobials in both health-
care and agriculture.2 In particular, unprecedented outbreaks of
CDI were caused by the epidemic RT 027 strain (A!B!CDT!). RT
027 spread globally from North America in the early 2000s, due
in part to acquired resistance to fluoroquinolones via a Thr82Ile
mutation (gyrA gene).3
C. difficile RT 027 has rarely been isolated in Asia-Pacific coun-
tries,4 but several other fluoroquinolone-resistant strains are
prominent in the region. The most common strain of C. difficile cir-
culating in Asia is RT 017, an A#B!CDT# strain that is particularly
prevalent in East and South-East Asia and is frequently reported as
fluoroquinolone resistant and clindamycin resistant.5,6 C. difficile
RT 017 notably caused outbreaks of CDI in Canada and Europe in
the late 1990s and early 2000s.6 Another A#B!CDT# strain, RT
369, is currently one of the most common circulating strains in
Japan and China and shows high rates of resistance to clindamycin
and moxifloxacin.4,7 C. difficile RT 018 (A!B!CDT#), another fre-
quently fluoroquinolone-resistant strain,8 predominates in north-
ern Asia, particularly in Japan and South Korea where, to some
extent, it has replaced RT 017.4,5
Recurrent CDI (rCDI) is a frequent and serious outcome of CDI,
due to slow recovery of host gut microbiota following treatment
with broad-spectrum antimicrobials. Recurrence rates reach as
high as 20% in North America and Europe.9,10 In Asia, rCDI rates
appear to be somewhat lower overall at 5%–10%;4,11 however, a
general lack of awareness and underdiagnosis of CDI in Asia5
may mean that reported recurrence rates are underestimated.
The heavy burden that rCDI places on healthcare systems has
driven exploratory research to develop therapeutic agents that will
eliminate C. difficile while preserving the gut microflora, to reduce
the likelihood of recurrence. One promising candidate therapeutic
agent is ridinilazole/SMT19969 [2,20-bis(4-pyridyl)3H,30H 5,50-
bibenzimidazole] (Summit Therapeutics Inc.), which has shown
highly specific inhibitory activity against C. difficile.12
The aim of this study was to evaluate the antimicrobial activity
of ridinilazole and six comparator antimicrobials against a collec-
tion of common C. difficile strains from northern Asia.
Methods
Study strain collection
A total of 140 C. difficile strains from clinical cases of CDI were selected for
testing from collections from Japan (n = 64, isolated in 2010), South Korea
(n = 32, isolated 2005–12) and China (n = 44, isolated 2010–11). Strains
were selected to represent the most common C. difficile strains circulating
in Asia, which included RTs 017, 369, 012, 014/020, 002, 046, 018, 001, 070,
127 and QX 029 (Table 1). In the case of RT 127, the only A!B!CDT! strain
included, a single strain was tested since it had caused a ward-based CDI
outbreak in a Tokyo hospital in 2010.13
Susceptibility testing by agar incorporation
Agar dilution susceptibility testing for ridinilazole, fidaxomicin, metronida-
zole, vancomycin, clindamycin, moxifloxacin and rifaximin was performed
according to the CLSI guidelines.14 Strains were recorded as susceptible to
fidaxomicin for MIC <1 mg/L8 and susceptible to metronidazole, vanco-
mycin, clindamycin and moxifloxacin for MICs of2 mg/L.8,14 Resistance to
metronidazole was recorded for MIC >2 mg/L, to vancomycin for MIC
>8 mg/L, to clindamycin and moxifloxacin for MICs8 mg/L8 and to rifaxi-
min for MIC 32 mg/L.15 Assays were performed a minimum of twice for
each strain; for all results presented, resistance profiles matched for each it-
eration of the study. Resistance rates, MIC50 and MIC90 and geometric
mean MICs were calculated for each RT.
Results
MICs for ridinilazole ranged from 0.03 to 0.25 mg/L, with an MIC50
of 0.125 mg/L (Table 1) and geometric mean MIC of 0.12 mg/L
overall. Similar MICs were recorded for fidaxomicin (range 0.015–
0.25 mg/L) with an MIC50 of 0.125 mg/L but lower geometric mean
MIC of 0.07 mg/L. All strains were susceptible to metronidazole
and vancomycin; one strain from China (RT 001) displayed inter-
mediate vancomycin resistance (MIC 4 mg/L) while all other
vancomycin MICs were recorded as2 mg/L.
Resistance to clindamycin was widespread (70.7% overall,
MIC50 of >32 mg/L, MIC90 of >32 mg/L and geometric mean MIC of
13.03 mg/L; Table 1), found in all RT 017 strains (geometric mean
MIC 30.62 mg/L) and in >80% of RT 369 (94.4%), RT 012 (92.3%),
RT 046 (81.8%), RT 018 (83.3%) and RT 001 (81.3%) (all MIC50s
and MIC90s >32 mg/L) strains. Clindamycin resistance was most
frequently found in strains from South Korea (80.9%), then China
(73.0%), then Japan (64.1%; Table 2).
Overall, 61.4% of strains were resistant to moxifloxacin, with an
MIC50 of 16 mg/L, MIC90 of 32 mg/L and geometric mean of
7.96 mg/L. Moxifloxacin resistance was present in all RT 369
strains, 91.3% of RT 017, 94.1% of RT 002 and 83.3% of RT 018
(Table 1). Resistance to moxifloxacin was rare in China (36.0% of
strains), found in 69.5% of strains from Japan and was widespread
among strains from South Korea (82.4%); all RT 017, RT 002, RT
001 and RT 018 strains from South Korea were moxifloxacin resist-
ant (Table 2).
Rifaximin resistance was rarer overall (16.4%, MIC50 of 0.03
mg/L, MIC90 of >32 mg/L, geometric mean MIC of 0.08 mg/L;
Table 1), found most frequently in RT 017 strains (82.6%) and
among some strains of RT 001 (12.5%), RT 070 (20.0%), RT 046
(9.1%) and RT 014/020 (5.3%). Rifaximin resistance was most
commonly found in strains from South Korea (33.8%); all RT 017
strains from South Korea and 91.7% of RT 017 from China were re-
sistant to rifaximin; however, no rifaximin resistance was detected
in any strains from Japan (Table 2).
Multiresistance to clindamycin, moxifloxacin and rifaximin was
found in 22 strains. These were mainly RT 017 strains from China
and South Korea (n = 19), plus two RT 001 strains (South Korea)
and one RT 046 strain (South Korea).
Discussion
The collection of Asian strains of C. difficile tested here showed
diverse antimicrobial susceptibility profiles, with high rates of re-
sistance to clindamycin and moxifloxacin. In particular, strains of
C. difficile RT 017, the predominant strain circulating in Asia, were
almost all multiresistant to clindamycin, moxifloxacin and rifaxi-
min. C. difficile RTs 369 and 018 also showed high resistance rates
and high geometric mean MICs for clindamycin and moxifloxacin
(Table 1). While the strains tested here were collected prior to
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Table 1. Overall susceptibility testing results
Resistant
MIC range MIC50 MIC90 Geometric mean
RT Agent n (%) (mg/L)
All (n = 140) RDZ 0 0.03–0.25 0.125 0.25 0.12
MTZ 0 0.06–0.5 0.25 0.25 0.18
VAN 0 0.06-4 1 2 1.13
CLI 99 (70.7) 0.125 to >32 >32 >32 13.03
MOX 86 (61.4) 1 to >32 16 32 7.96
RFX 23 (16.4) 0.002 to >32 0.03 >32 0.08
FDX 0 0.015–0.25 0.125 0.25 0.07
RT 017 (n = 23) RDZ 0 0.03–0.125 0.125 0.25 0.11
MTZ 0 0.06–0.25 0.125 0.25 0.16
VAN 0 0.06–2 1 2 0.86
CLI 23 (100.0) 8 to >32 >32 >32 30.62
MOX 21 (91.3) 1 to >32 32 32 21.81
RFX 19 (82.6) 0.008 to >32 >32 >32 7.63
FDX 0 0.015–0.125 0.06 0.125 0.06
RT 014/020 (n = 19) RDZ 0 0.06–0.25 0.125 0.125 0.11
MTZ 0 0.06–0.25 0.25 0.25 0.20
VAN 0 0.5–2 1 2 1.36
CLI 4 (21.1) 0.25 to >32 4 16 2.83
MOX 4 (21.1) 1–32 2 16 3.39
RFX 1 (5.3) 0.005–32 0.015 0.03 0.02
FDX 0 0.03–0.25 0.125 0.125 0.08
RT 369 (n = 18) RDZ 0 0.06–0.25 0.125 0.25 0.16
MTZ 0 0.125–0.25 0.25 0.25 0.18
VAN 0 0.5–2 1 1 1.00
CLI 17 (94.4) 0.25 to >32 >32 >32 26.40
MOX 18 (100.0) 8 to >32 16 16 13.45
RFX 0 0.015–0.03 0.03 0.03 0.02
FDX 0 0.03–0.25 0.125 0.25 0.09
RT 002 (n = 17) RDZ 0 0.03–0.25 0.125 0.25 0.12
MTZ 0 0.125–0.5 0.25 0.25 0.20
VAN 0 0.125–2 1 2 1.17
CLI 10 (58.8) 0.25 to >32 >32 >32 8.16
MXF 16 (94.1) 1 to >32 32 >32 19.89
RFX 0 0.008–0.03 0.015 0.03 0.02
FDX 0 0.015–0.25 0.06 0.125 0.08
RT 001 (n = 16) RDZ 0 0.06–0.125 0.125 0.125 0.09
MTZ 0 0.125–0.25 0.25 0.25 0.18
VAN 0 0.06–4 1 2 0.94
CLI 13 (81.3) 0.25 to >32 >32 >32 19.03
MOX 11 (68.8) 1 to >32 8 16 6.11
RFX 2 (12.5) 0.008 to >32 0.03 >32 0.24
FDX 0 0.015–0.25 0.03 0.06 0.04
RT 012 (n = 13) RDZ 0 0.06–0.25 0.125 0.125 0.11
MTZ 0 0.125–0.5 0.25 0.25 0.23
VAN 0 1–2 2 2 1.57
CLI 12 (92.3) 4 to >32 >32 >32 27.27
MOX 0 2 2 2 2.00
RFX 0 0.008–0.03 0.015 0.03 0.02
FDX 0 0.03–0.25 0.125 0.25 0.10
RT 018 (n = 12) RDZ 0 0.06–0.125 0.125 0.125 0.11
MTZ 0 0.125–0.25 0.125 0.25 0.17
Continued
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patterns.16 The circulation of strains with enhanced resistance pro-
files warrants regular surveillance and stewardship of prescribing
practices.
Ridinilazole and fidaxomicin were both potently active against
C. difficile. The low MICs found here agreed with previous reports.12
Fidaxomicin is already in therapeutic use in several countries and
fidaxomicin-resistant C. difficile strains have been reported in rare
cases.17 Ridinilazole is currently in Phase III clinical trials; to date,
no resistance to ridinilazole has been reported.
No resistance to metronidazole or vancomycin was found. One
strain (an RT 001 strain from China) showed borderline resistance
to vancomycin (4 mg/L) according to EUCAST epidemiological cut-
off values (>2 mg/L, www.eucast.org), but was considered as inter-
mediately resistant according to Freeman et al.8 (breakpoint
>8 mg/L). Increased MICs implying intermediate or complete
resistance to vancomycin have been reported previously,8 as have
increased MICs to metronidazole, including among A#B#CDT#
C. difficile strains,18 which circulate widely in Asia. These findings
highlight a need for continuing surveillance for changes in suscep-
tibility of C. difficile to metronidazole and vancomycin worldwide.
Notably, no rifaximin resistance was detected in strains from
Japan, compared with the high rates seen among RT 017 strains
from China and South Korea (Table 2). Rifaximin was only intro-
duced in Japan in November 2016, after the strains tested here
were collected.19 Rifaximin resistance may now emerge among
C. difficile strains in Japan, as rapid emergence of rifaximin/
rifampin resistance following treatment with rifaximin has been
demonstrated in Staphylococcus aureus and in C. difficile.15,20 The
fact that C. difficile strains from neighbouring China and/or South
Korea had comparatively high rates of resistance to rifaximin
Table 1. Continued
Resistant
MIC range MIC50 MIC90 Geometric mean
RT Agent n (%) (mg/L)
VAN 0 0.25–2 1 2 1.14
CLI 10 (83.3) 0.25 to >32 >32 >32 18.28
MOX 10 (83.3) 2–32 32 32 16.88
RFX 0 0.008–16 0.015 0.03 0.02
FDX 0 0.03–0.125 0.06 0.125 0.06
RT 046 (n = 11) RDZ 0 0.06–0.25 0.125 0.125 0.12
MTZ 0 0.125–0.25 0.25 0.25 0.19
VAN 0 0.06–2 2 2 1.50
CLI 9 (81.8) 0.125 to >32 >32 >32 18.15
MOX 2 (18.2) 1–16 2 16 2.27
RFX 1 (9.1) 0.008 to >32 0.015 0.03 0.03
FDX 0 0.06–0.25 0.125 0.125 0.09
QX 029 (n = 6) RDZ 0 0.06–0.25 0.125 0.12
MTZ 0 0.125–0.25 0.25 0.19
VAN 0 0.25–2 1 0.84
CLI 1 (16.7) 0.25 to >32 4 2.24
MOX 4 (66.7) 1–32 16 10.08
RFX 0 0.008–0.03 0.03 0.02
FDX 0 0.06–0.25 0.125 0.10
RT 070 (n = 4) RDZ 0 0.125 0.125 0.13
MTZ 0 0.06–0.25 0.25 0.18
VAN 0 2 2 2.00
CLI 0 0.5–4 2 2.00
MOX 0 2 2 2.00
RFX 1 (20.0) 0.015–0.03 0.03 0.02
FDX 0 0.06–0.125 0.06 0.09
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implies there is little movement of C. difficile strains between the
countries, at least into Japan.
In conclusion, ridinilazole showed excellent activity against a
range of C. difficile strains from Asian countries, which were frequent-
ly multiresistant to clindamycin, moxifloxacin and rifaximin.
Dependent on the outcome of Phase III trials that are currently
underway, ridinilazole appears to be a strong candidate for first-line
therapy for CDI not only in Asia but elsewhere; however, cost-
effectiveness of treatment with ridinilazole versus other antimicro-
bials must be considered, especially in lower-income Asian countries.
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